Please login to the form below
DS Biopharma promotes Dr Markus Weissbach
He moves to chief operating officer at the Irish drug discovery firm
Dr Markus Weissbach has been appointed chief operating officer at Irish drug discovery and development company DS Biopharma.
He previously served as the Dublin-based firm's medical director, which he joined after a spell running his own consultancy.
Prior to that his 25years in the pharma, biotech and CRO industries saw him hold senior roles that included chief medical officer (Europe) at Novartis Vaccines and Diagnostics, president of Icon Clinical Research (Europe) and director of clinical research and development at Takeda R&D (Europe).
Commenting on his new appointed, DS Biopharma's executive chairman Dr John Climax said: “I am delighted to welcome Dr Markus Weissbach into his new role within the DS team and I look forward to working with him in advancing the DS portfolio.”
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Europe’s cancer community publishes new report on transforming patient care
- Assessing the value of interim analyses in clinical trials
- Piloting a route to the biosimilars opportunities in Europe
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
